Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up reviews of suspected throat cancer. The technology consists of an ...

Identifying the difference between customer and patient experiences in healthcare and why they shouldn’t be confused is integral to organisations delivering their services to people. Healthcare ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Today, we live in an age of artificial intelligence (AI); more specifically, the age of generative AI (GenAI). In a recent report, 65% of respondents stated that their organisations are regularly ...

Life sciences companies around the globe are grappling with the question of whether and how to deploy generative artificial intelligence (GenAI) tools, including use in streamlining company processes.

At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers. The US regulator approved Vyloy ...

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas. Under the ...

The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.

Pharma marketing is evolving and it’s evolving quickly. Old ideas about static, one-size-fits-all content generation are giving way to approaches like modular content, dynamic content ...